Nano-hydroxyapatite radiolabeled with radium dichloride [223Ra] RaCl2 for bone cancer targeted alpha therapy: In vitro assay and radiation effect on the nanostructure
Makaleler > Tam Makale · 2023
Yazarlar: Sara Gemini-Piperni, Eduardo Ricci-Junior, Derya İLEM ÖZDEMİR, Beatriz da Silva Batista, Luciana Magalhães Rebelo Alencar, Alexandre Malta Rossi, Ralph Santos-Oliveira
Colloids and Surfaces B: Biointerfaces, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2023, cilt 223, ss 113174-113174
DOI: 10.1016/j.colsurfb.2023.113174
Özet
The use of targeted alpha therapy (TAT) for bone cancer is increasing each year. Among the alpha radionuclides , radium [ 223 Ra]Ra +2 is the first one approved for bone cancer metastasis therapy. The development of novel radiopharmaceutical based on [ 223 Ra]Ra +2 is essential to continuously increase the arsenal of new TAT drugs . In this study we have developed, characterized, and in vitro evaluated [ 223 Ra] Ra-nano-hydroxyapatite. The results showed that [ 223 Ra] Ra-nano-hydroxyapatite has a dose-response relationship for osteosarcoma cells and a safety profile for human fibroblast cells, corroborating the application as a radiopharmaceutical.